Skip to content

A pacemaker study evaluating two algorithms for better pacing management

South Asia Study- Evaluation of VentriculAr Intrinsic Preference Plus VentricuLar AutoCapture Features In Dual ChAmber Pacemaker PaTiEnts (VALIDATE)

Status
Active, not recruiting
Phases
Phase 4
Study type
Observational
Source
CTRI
Registry ID
CTRI/2010/091/000179
Enrollment
80
Registered
2010-09-15
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Bradycardia

Interventions

Intervention1: VIP ON and VAC ON: 12 Months Control Intervention1: VIP OFF and VAC OFF: 12 Months

Sponsors

St Jude Medical Hong Kong Pvt Ltd
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients who have an indication for implantation of a dual chamber pacemaker according to the ACC / AHA / HRS guidelines 2. Patients must be able and willing to provide written informed consent to participate in the clinical study 3. Patient is geographically stable and willing to comply with the required follow-up schedule

Exclusion criteria

Exclusion criteria: 1. Patient has permanent AV block 2. Patient has persistent or permanent AF/AFL 3. Patient has pacemaker replacement 4. Patient is in NYHA Class IV 5. Patient is pregnant 6. Patient is less than 18 years old 7. Patient?s life expectancy is less than 12 months.

Design outcomes

Primary

MeasureTime frame
To demonstrate that the Ventricular Intrinsic Preference (VIPTM) and Ventricular AutoCapture (VAC) features allow better RV pacing management, which helps in reducing the long-term incidence of unnecessary right ventricular (RV) pacing in patients with compromised / intact AV conduction.Timepoint: 12 months

Secondary

MeasureTime frame
Incidence of AV blocks; Percentage of VAC accuracy in ventricular pacing threshold measurements (Manual vs. Auto);Incidence of cardiovascular adverse events;Incidence of device related adverse events; Proportion of patients with symptomsTimepoint: 3, 6 and 12 months

Countries

Bangladesh, India

Contacts

Public ContactSumit Anand
upendra.kaul@fortishealthcare.com011- 47134231

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026